Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for prevention of diabetic macular edema after cataract surgery in diabetic retinopathy
2011-006063-22Phase 4Completed
- Sponsor
- Fundación Oftalmológica del Mediterráneo
- Start
- Jan 2012
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Fundación Oftalmológica del Mediterráneo. Primary endpoint: Central macular thickness at 6 months. Started Jan 2012; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2011-006063-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006063-22.